Text Size

Topical Diclofenac Gel in Patients With Superficial Inflammation of the Veins

This study has been completed.
Sponsor:
Information provided by:
Novartis
ClinicalTrials.gov Identifier:
NCT00377806
First received: September 15, 2006
Last updated: December 7, 2007
Last verified: December 2007
History of Changes
  Purpose

This study will assess the efficacy, safety and tolerability of topically administered diclofenac gel versus placebo with respect to the symptom score (pain, temperature and size of erythema along the superficial vein)


Condition Intervention Phase
Superficial Thrombophlebitis of the Upper Limb
 Drug: Diclofenac gel
 Phase 4

Study Type: Interventional
Study Design: Allocation: Randomized
Endpoint Classification: Safety/Efficacy Study
Intervention Model: Parallel Assignment
Masking: Double-Blind
Primary Purpose: Treatment
Official Title: A One Week, Double-Blind, Adaptive, Randomized, Multicenter Study to Compare the Efficacy, Safety and Tolerability of Topical Diclofenac Gel Versus Placebo in Patients With Superficial Thrombophlebitis

Resource links provided by NLM:

U.S. FDA Resources

Further study details as provided by Novartis:

Primary Outcome Measures:
  • The area under the curve (AUC) of the symptom score (pain, temperature and size of erythema along the superficial vein)

Secondary Outcome Measures:
  • Patient's global assessment of drug effect at each visit
  • Physician's global assessment of drug effect at each visit
  • AUC of assessment of pain (visual analog scale) between treatment day 1 and day 5
  • AUC of assessment of inflammatory area of the superficial thrombophlebitis between treatment day 1 and 5
  • AUC of assessment of temperature of inflammatory area around superficial thrombophlebitis between treatment day 1 and 5

Estimated Enrollment: 200
Study Start Date: January 2003
Study Completion Date: September 2006
  Eligibility

Ages Eligible for Study:   18 Years to 85 Years
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Patients with indication of topical treatment for inflammatory, painful superficial thrombophlebitis of the upper limb
  • Spontaneous or iatrogenic superficial thrombophebitis of the upper limb

Exclusion Criteria:

  • Hypersensitivity to the study drug, to actylsalicyclic acid and other non-steroidal antirheumatic agents and to the ingredients of the gel
  • Paitents who had developed asthma, skin reactions or acute rhinitis to acetylsalicylic acid or other non-steroidal antirheumatic agents in the past
  • Therapy with varicose vein remedies, antithrombotic or antiphlogistic agents as well as corticosteroids for more than 7 days prior to study start
  • Acute deep vein thrombosis and thrombophlebitis extending into other deep veins

Other protocol-defined exclusion criteria may apply

  Contacts and Locations
Please refer to this study by its ClinicalTrials.gov identifier: NCT00377806

Locations
Germany
Novartis
Nürnberg, Germany
Sponsors and Collaborators
Novartis
Investigators
Principal Investigator: Novartis Pharmaceuticals Novartis Pharmaceuticals
  More Information

No publications provided

ClinicalTrials.gov Identifier: NCT00377806     History of Changes
Other Study ID Numbers: CVOL458UDE01
Study First Received: September 15, 2006
Last Updated: December 7, 2007
Health Authority: Germany: Federal Institute for Drugs and Medical Devices

Keywords provided by Novartis:
Superficial thrombophlebitis, diclofenac gel, non steroidal antiinflammatory drugs

Additional relevant MeSH terms:
Phlebitis
Thrombophlebitis
Peripheral Vascular Diseases
Vascular Diseases
Cardiovascular Diseases
Vasculitis
Venous Thrombosis
Thrombosis
Embolism and Thrombosis
Anti-Inflammatory Agents, Non-Steroidal
Diclofenac
Analgesics, Non-Narcotic
 Analgesics
Sensory System Agents
Peripheral Nervous System Agents
Physiological Effects of Drugs
Pharmacologic Actions
Anti-Inflammatory Agents
Therapeutic Uses
Antirheumatic Agents
Cyclooxygenase Inhibitors
Enzyme Inhibitors
Molecular Mechanisms of Pharmacological Action
Central Nervous System Agents

ClinicalTrials.gov processed this record on May 23, 2013